Evaluation of immunotoxicity of the extended-release form of Afobazol
https://doi.org/10.37489/2587-7836-2020-3-48-51
Abstract
The research of immunotoxicity of extended-release form of Afobazol was conducted on male CBA, C57BL/6 and F1 hybrids (CBA×C57BL/6) mice. Afobazol was administered per os for 14 days in doses of 12 mg/kg and 120 mg/kg. Control group received a placebo. Weight of thymus, spleen and popliteal lymph nodes was not affected by the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg in F1 hybrids (CBA×C57BL/6) mice compared to the control group (p> 0.05). Cellularity of thymus was significantly increased by the extended-release form of Afobazol in dose of 12 mg/kg (p< 0.01 vs control group). Administration of the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg decreased spontaneous chemiluminescence activity of peripheral blood lymphocytes in 2.0 and 2.2 times, in dose of 120 mg/kg level integral chemiluminescence response S was decreased in 2.4 times (p< 0.05 vs control group). Phagocytic activity of peritoneal macrophages and antibody production in F1 hybrids (CBA×C57BL/6) mice were not affected by administration of the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg (p > 0.05 vs control group). 14 days of the extended-release form of Afobazol in doses of 12 mg/kg and 120 mg/kg did not cause any significant change to intensity of delayed-type hypersensitivity reactions (p> 0.05 vs control group). The results of the study allow us to conclude that administration of the extended-release form Afobazol in the range of studied doses does not induce immunotoxicity.
About the Authors
L. P. KovalenkoRussian Federation
Kovalenko Larisa P., D. Sci. in Biology, Leading Researcher of drug
toxicology department
SPIN code: 5185-4250
R. V. Zhurikov
Russian Federation
Zhurikov Ruslan V. , Junior researcher of laboratory of drug toxicology
SPIN code: 6648-1794
K. V. Korzhova
Russian Federation
Korzhova Ksenia V., Junior researcher of laboratory of drug toxicology
SPIN code: 3831-3782
A. D. Durnev
Russian Federation
Durnev Andrei D., D. Sci. in Medicine, professor, RAS corresponding member of the RAS, Head of the department of drug toxicology, Director
SPIN code: 8426-0380
References
1. Seredenin SB, Voronin MV. Neuroreceptor mechanisms involved in the action of afobazole. Eksperimental'naia i klinicheskaia farmakologiia. 2009;72(1):3–11. (In Russ).]. DOI: 10.30906/0869-2092-2009-72-1-3-11.
2. Kadnikov IA, Voronin MV, Seredenin SB. Effect of afobazole on the activity of quinone reductase 2. Khimiko-farmatsevticheskii zhurnal.2013:47(10);9–11. (In Russ).]. DOI: 10.30906/0023-1134-2013-47-10-9-11.
3. Haitov RM, Ivanova AS, Kovalenko LP, et al. Metodicheskie rekomendacii po ocenke immunotoksicheskogo dejstviya farmakologicheskih veshchestv. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. Part one. /Ed by AN Mironova. Moscow: Grif i K; 2012. p. 64–79. (In Russ).].
4. Haitov RM, Gushchin IS, Pinegin BV, et al. Metodicheskie rekomendacii po doklinicheskomu izucheniyu immunotropnoj aktivnosti farmakologicheskih veshchestv. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. Part one. / Ed by AN Mironova. Moscow: Grif i K; 2012. p. 626–656. (In Russ).].
Review
For citations:
Kovalenko L.P., Zhurikov R.V., Korzhova K.V., Durnev A.D. Evaluation of immunotoxicity of the extended-release form of Afobazol. Pharmacokinetics and Pharmacodynamics. 2020;(3):48-51. (In Russ.) https://doi.org/10.37489/2587-7836-2020-3-48-51